The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

U.S. stock futures were little changed on Thursday night after the major averages slid following a lackluster earnings ...